标题
Antibodies to watch in 2019
作者
关键词
-
出版物
mAbs
Volume -, Issue -, Pages 1-20
出版商
Informa UK Limited
发表日期
2018-12-05
DOI
10.1080/19420862.2018.1556465
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study
- (2018) Hongnan Mo et al. BRITISH JOURNAL OF CANCER
- Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials
- (2018) A. Blauvelt et al. BRITISH JOURNAL OF DERMATOLOGY
- The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions
- (2018) Tong Zhang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma
- (2018) Jing Huang et al. CLINICAL CANCER RESEARCH
- CCR5: Established paradigms and new frontiers for a ‘celebrity’ chemokine receptor
- (2018) Ilaria Scurci et al. CYTOKINE
- Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design
- (2018) Paul G Richardson et al. Future Oncology
- Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine
- (2018) David W. Dodick et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis
- (2018) Karl L Insogna et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
- (2018) Robert J. Kreitman et al. LEUKEMIA
- Antibodies to watch in 2018
- (2018) Hélène Kaplon et al. mAbs
- Next generation immune-checkpoints for cancer therapy
- (2018) Chiara Donini et al. Journal of Thoracic Disease
- Sickle cell disease
- (2018) Gregory J. Kato et al. Nature Reviews Disease Primers
- Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
- (2018) Kenneth B Gordon et al. LANCET
- Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials
- (2018) Wenfeng Fang et al. LANCET ONCOLOGY
- Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1
- (2018) Brinda Emu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis
- (2018) Abdullah Kutlar et al. AMERICAN JOURNAL OF HEMATOLOGY
- Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study
- (2018) Jianming Xu et al. CLINICAL CANCER RESEARCH
- Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
- (2017) Kristian Reich et al. LANCET
- Antibodies to watch in 2017
- (2016) Janice M. Reichert mAbs
- Phage display-derived human antibodies in clinical development and therapy
- (2016) André Frenzel et al. mAbs
- Antibodies to watch in 2016
- (2015) Janice M. Reichert mAbs
- Antibodies to watch in 2015
- (2014) Janice M Reichert mAbs
- Clinical development success rates for investigational drugs
- (2014) Michael Hay et al. NATURE BIOTECHNOLOGY
- The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients
- (2013) C Kellner et al. LEUKEMIA
- Antibodies to watch in 2014
- (2013) Janice M Reichert mAbs
- Which are the antibodies to watch in 2013?
- (2013) Janice M. Reichert mAbs
- Drugs derived from phage display
- (2013) Andrew E Nixon et al. mAbs
- Which are the antibodies to watch in 2012?
- (2012) Janice M. Reichert mAbs
- Marketing approval of mogamulizumab
- (2012) Alain Beck et al. mAbs
- Immunotoxins with decreased immunogenicity and improved activity
- (2011) Ira Pastan et al. LEUKEMIA & LYMPHOMA
- Antibody-based therapeutics to watch in 2011
- (2011) Janice M. Reichert mAbs
- Antibodies to watch in 2010
- (2010) Janice M. Reichert mAbs
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started